Lung Carcinoma Clinical Trial
Official title:
A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer
Verified date | June 2024 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot phase I trial studies the side effects and how well MUC1 peptide-Poly-ICLC vaccine works in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer.
Status | Active, not recruiting |
Enrollment | 50 |
Est. completion date | December 1, 2024 |
Est. primary completion date | September 23, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years to 80 Years |
Eligibility | Inclusion Criteria: - PRE-REGISTRATION INCLUSION CRITERIA - Smoking history of >= 30 pack-years AND either current smoker (still smoking or quit < 1 year prior to pre-registration) OR former smoker (quit 1-15 years prior to pre-registration); Note: Pack years is determined by multiplying the number of packs smoked per day by the number of years smoked - Eastern Cooperative Oncology Group (ECOG) performance status =< 1 - Computed tomography (CT) scan of the chest done =< 6 months prior to pre-registration showing either negative findings (no nodules) or solid or part-solid nodules < 6 mm in size (consistent with < 1% probability of malignancy, Lung-Reporting and Data Systems [RADs] version 1.0) - Willingness to employ adequate contraception, if applicable; Note: women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately - Ability to understand and the willingness to sign a written informed consent document - REGISTRATION INCLUSION CRITERIA - Leukocytes (white blood cell [WBC]) >= 3,000/microliter - Neutrophils (absolute neutrophil count [ANC]) >= 1,500/microliter - Platelets >= 100,000/microliter - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) Note: Higher total bilirubin levels (=< 3 mg/dL) can be allowed if due to known benign liver condition, i.e. Gilbert's - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 1.5 x institutional upper limit of normal (ULN) - Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional upper limit of normal (ULN) - Creatinine =< institutional upper limit of normal (ULN) Exclusion Criteria: - PRE-REGISTRATION EXCLUSION CRITERIA - History of any malignancy; exceptions: non-melanoma skin cancer or carcinoma in situ (CIS) of the cervix - Known hepatitis B or C - Receiving any other investigational agents - Any prior investigational immune therapy, such as for lung cancer prevention or treatment or for CIS of the cervix - Use of oral or systemic steroids or other systemic anti-immune therapy =< 90 days prior to pre-registration; Note: Use of inhaled/nasal steroids and local steroid injections for pain control are not exclusionary - Known human immunodeficiency virus (HIV) - Known autoimmune disease - Known non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) - History of allergic reactions attributed to compounds of similar chemical or biologic composition to MUC1/Poly-ICLC - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - REGISTRATION EXCLUSION CRITERIA - Any positive antinuclear antibody (ANA) titer above 1:160, even in an asymptomatic individual. Note: Weakly positive ANA defined as ANA titers up to 1:160 maximum (=< 1:160) will be acceptable in an asymptomatic individual who is otherwise eligible for the study - Pregnant or breast feeding; Note: Pregnant women are excluded from this study because the MUC1/Poly-ICLC vaccine may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with MUC1/Poly-ICLC vaccine, breastfeeding should be discontinued if the mother is treated with the vaccine |
Country | Name | City | State |
---|---|---|---|
United States | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania |
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Chronic Obstructive Pulmonary Disease (COPD) Status | Will explore the relationship between COPD status at pre-registration and immune response in current versus former smokers. In individuals with COPD, the severity of airflow obstruction will be measured by the pulmonary function tests as per the GOLD classification. | Baseline to week 12 | |
Other | Changes in Immunogenicity in Individuals With Chronic Obstructive Pulmonary Disease (COPD) | Will explore whether or not changes in immunogenicity in individuals with COPD corresponds to different circulating MDSC levels. | Baseline up to week 12 | |
Other | Impact of the MUC1/Poly-ICLC Vaccine on Inflammation-Related High Sensitivity C-Reactive Protein (hsCRP) and Interleukin-6 (IL-6) | Up to week 24 | ||
Other | Ability to Successfully Vaccinate With MUC1/Poly-ICLC Vaccine Depending on Baseline High Sensitivity C-Reactive Protein (hsCRP) and Interleukin-6 (IL-6) Levels | Up to week 24 | ||
Primary | Number of Participants With Immunogenicity of the MUC1 Vaccine | Will be evaluated by monitoring changes in IgG anti-MUC1 antibody titer ratio; defined as t12/t0, where t0 is the "initial titer" measured prior to vaccination, and t12 is the "final titer" drawn at 12 weeks. A titer ratio of >= 2 will be considered a positive response. | At week 12 | |
Primary | Count of Patients Experiencing 1 or More Grade 3+ Adverse Events at Least Possibly Related to Treatment | Will be assessed according to National Cancer Institute Common Toxicity Criteria version 4.0. The maximum grade for each type of adverse event will be recorded for each participant and frequency tables will be reviewed to determine the overall patterns. In addition, the number and severity of adverse events will be tabulated and summarized across all grades. | 24 weeks | |
Secondary | Effect of Smoking Status on Vaccine Response | To explore potential differences, if any, in the immunogenicity of the vaccine (as assessed at week 12 by the IgG anti-MUC1 antibody titer ratio) in current vs. former smokers. | 12 weeks | |
Secondary | Pre-Vaccination Levels Versus Post-Vaccination Levels of Circulating Myeloid Derived Suppressor Cells (MDSC) | Will correlate with the ability to respond to the vaccine. Will summarize the data using descriptive statistics and graphical methods (i.e. boxplots, scatter plots, etc.). For continuous MDSC data versus response data, will use t-tests or Wilcoxon Rank-Sum tests (for non-normal data). | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04931017 -
Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Not yet recruiting |
NCT06038526 -
Evaluation of Canakinumab in High-Risk Former-Smokers
|
Phase 2 | |
Terminated |
NCT02856581 -
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
|
Phase 3 | |
Completed |
NCT04922697 -
Educational Intervention for the Promotion of Knowledge and Preventive Health Behaviors Related to Personal Air Pollution Exposure, The Air Study
|
N/A | |
Recruiting |
NCT04644952 -
The Rise in Robotic Atypical Segmentectomies
|
||
Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
Recruiting |
NCT05407168 -
Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool
|
N/A | |
Completed |
NCT04267874 -
Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study
|
Early Phase 1 | |
Recruiting |
NCT02408861 -
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Recruiting |
NCT03709953 -
Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03267524 -
Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers
|
N/A | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Completed |
NCT02237183 -
Iloprost in Preventing Lung Cancer in Former Smokers
|
Phase 1 | |
Recruiting |
NCT04783168 -
Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study
|
N/A | |
Completed |
NCT04635761 -
Awareness, Information, and Resources for Lung Cancer Screening Program for Community-Partnered Lung Cancer Screening
|
N/A | |
Recruiting |
NCT06445192 -
Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial
|
N/A | |
Active, not recruiting |
NCT03164486 -
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
|
Early Phase 1 | |
Recruiting |
NCT05802186 -
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
|
N/A | |
Active, not recruiting |
NCT01696968 -
Screening for Lung Cancer in Older Patients (PLCO Screening Trial)
|
N/A |